Optimal Targeting of HER2–PI3K Signaling in Breast Cancer: Mechanistic Insights and Clinical Implications
Cet article passe en revue les perspectives cliniques offertes par les travaux récents sur la combinaison d'un inhibiteur de PI3K et du trastuzumab pour le traitement des patientes atteintes d'un cancer du sein HER2+
The combination of a PI3K inhibitor with trastuzumab has been shown to be effective at overcoming trastuzumab resistance in models of HER2+ breast cancer by inhibiting HER2–PI3K–FOXO–survivin signaling. In this review the potential clinical implications of these findings are discussed. Cancer Res; 73(13); 1–4. ©2013 AACR.